Pfizer Stock Earnings Reports

Pfizer delivered a strong start to 2026, beating expectations for revenue ($14.5B) and adjusted EPS ($0.75) in Q1. Management highlighted execution across four strategic priorities: advancing a robust R&D pipeline (targeting ~20 pivotal starts, 8 key readouts and 4 regulatory decisions in 2026), scaling launched and recently acquired products (22% operational growth for launched/acquired products, Nurtec up 41%), and focused commercial execution (notable contributors: Padcev, Eliquis, Nurtec, Lorbrena, Vyndaqel family). Two legal developments materially improved Pfizer's medium-term outlook: settlements related to Vyndamax push exclusivity later (providing increased confidence in entering a high single-digit 5-year revenue CAGR starting in 2029) and a favorable Belgian court decision on Comirnaty contracts that improves EPS and cash flow visibility. Financially, management reaffirmed 2026 guidance (revenues $59.5B–$62.5B; adjusted EPS $2.80–$3.00), reported adjusted gross margin in the mid-70s and progress on cost savings ($175M realized in Q1 toward ~$700M Phase I manufacturing savings this year and a $7.2B net cost savings target by year-end). Capital allocation priorities remain: invest in R&D and BD, maintain and over time grow the dividend, preserve optionality for buybacks (BD capacity ~ $7B including recent proceeds). Key growth drivers cited for late-decade acceleration include oncology (Seagen assets, Padcev, Elrexfio), metabolic/obesity programs (Metsera portfolio targeting a 2028 approval for a monthly maintenance option), vaccines (advancing higher-valency pneumococcal candidates including a 35‑serotype adult candidate), and continued penetration of recently acquired launches.